Vor Biopharma
59 hedge funds and large institutions have $326M invested in Vor Biopharma in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 7 closing their positions.
1,617% more call options, than puts
Call options by funds: $103K | Put options by funds: $6K
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
4% more funds holding
Funds holding: 57 → 59 (+2)
3.22% less ownership
Funds ownership: 7.78% → 4.56% (-3.2%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less capital invested
Capital invested by funds: $400M → $326M (-$74.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.15M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.75M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.57M |
| 4 |
BlackRock
New York
|
+$1.28M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$827K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.61M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$873K |
| 3 |
Walleye Capital
New York
|
-$814K |
| 4 |
AIC
AWM Investment Company
New York
|
-$665K |
| 5 |
Janus Henderson Group
London,
|
-$530K |
VOR Hedge Fund Activity: Q1 2023 in Review
59 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2023, worth a combined $326M — down 19% from $400M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VOR positions and 7 closed out — a net gain of 2 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.15M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.61M.
- 59 institutional investors held Vor Biopharma (VOR) as of Q1 2023, up from 57 in Q4 2022.
- Funds reported $326M of Vor Biopharma stock for Q1 2023, down 19% quarter-over-quarter.
- 9 funds opened new Vor Biopharma positions in Q1 2023 and 7 closed out, a net change of +2 holders.
- The largest Vor Biopharma buyer in Q1 2023 was Vanguard Group, an estimated $2.15M added.
- The largest Vor Biopharma seller in Q1 2023 was Baker Bros. Advisors, an estimated $4.61M sold.
Based on aggregated 13F filings for Q1 2023.